User:Marvin O'Neal/VlsE: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older edit
No edit summary
Jaime Prilusky (talk | contribs)
ConfirmAccount, Editor, Mutation, Next, Print3D, Tester, any2jmol, Bureaucrats, Interface administrators, journal, print3d, Administrators
8,777 edits
 
(146 intermediate revisions by 3 users not shown)
Line 1: Line 1:
Hi.
<table width='400' align='right' cellpadding='5'><tr><td rowspan='2'>&nbsp;</td><td bgcolor='#eeeeee'><applet load='1l8w.pdb' size='400' frame='true' align='right' scene='Studio:G5SecL01/Main_image_vlse/1' /></td></tr><tr><td bgcolor='#eeeeee'><center>'''Variable Major Protein (VMP)-like sequence Expressed''' ([[1l8w]]), resolution 2.3&Aring;
[[Image:VLSE PRIMARY STRUCTURE4343.png|400px]]<br>
<nowiki>*</nowiki><small>'''This representation of VlsE illustrates the only crystal structure available on the [http://www.rcsb.org/pdb/explore/explore.do?structureId=1l8w PDB site]. There are 10<sup>30</sup> possible combinations of the VR.'''</small>
<br></center></td></tr></table>
 
 
 
 
==Structural Overview==
 
 
Variable Major Protein (VMP)-like sequence Expressed ('''VlsE''') is a surface lipoprotein of ''Borrelia burgdorferi'', the causative agent of [http://en.wikipedia.org/wiki/Lyme_disease Lyme Disease].  It undergoes [http://en.wikipedia.org/wiki/Antigenic_variation antigenic variation] seemingly important in evasion of the host’s immune system.  In addition, the protein is used for Lyme disease diagnosis.  It is composed of four similar subunits each possessing two invariable domains and one variable domain.<ref name="A">PMID:10569796</ref>  The variable domain contains six variable regions (VR<sub>1</sub>-VR<sub>6</sub>), and six invariable regions (IR<sub>1</sub>-IR<sub>6</sub>).  Research suggests that the protein may exist as a dimer where each monomeric C & N termini neighbor each other forming the membrane proximal portion of the protein, and the variable regions form the membrane distal portion.<ref name="B">PMID:11923306</ref> <ref name="C">PMID:11716485</ref>    The invariable regions are largely embedded in the protein and remain relatively unchanged within the host and across strains.  The variable regions encompass 37% of the VlsE’s exposed surface area despite comprising only 25% of the protein.<ref name="A" /> <ref name="B" />  However, 50% of the VR surface area is exposed while IR<sub>6</sub>, a strong [http://en.wikipedia.org/wiki/Antigen antigen], exposes just 13.7% of its surface area.  This leaves only <scene name='Studio:G5SecL01/Ir_6_4_residues/1'>four amino residues</scene> of the antigenic IR<sub>6</sub> unprotected: lysine-276, glutamine-279, lysine-291, and lysine-294.  Thus, it is almost entirely embedded in the protein and <scene name='Studio:G5SecL01/Ir6_embedded/1'>sheilded by the variable regions </scene>.<ref name="B" /> <br>
 
 
 
 
==Antigenicity==
 
 
The variable regions undergo a recombination event stimulated by the host’s cytokines and absence of those cytokines results in a decreased bacterial burden.<ref name="D">PMID:11544329</ref>  This leads to variation with an estimated 10<sup>30</sup> possible combinations, far exceeding the number of antibodies found in the human immune system.  While the VR does exhibit antigenicity, this recombination makes it unlikely that a sufficient amount of a single VR variation will be present in large enough supply to lead to an immunodominant variable region.<ref name="E">PMID:10553085</ref>  IR<sub>6</sub>, however, exhibits immunodominance while IR<sub>1</sub>-IR<sub>5</sub> are primarily nonantigenic in humans.  Thus, shielding of the immunodominant IR<sub>6</sub> by VR regions not subject to antibody response allows for IR<sub>6</sub> to elicit an immune response while remaining inaccessible to antibody binding.  Research suggests that the 26 amino residues of <scene name='Studio:G5SecL01/Ir6_with_epitope/1'>IR6</scene> may function as a single epitope with a central alpha helical core.<ref name="B" /> <ref name="D" /> <ref name="F">PMID:10722641</ref> 
 
 
 
 
==Function in Immune System Evasion==
 
 
VlsE is essential to the persistence and virulence of Lyme disease and is upregulated under humoral immune pressure.<ref name="G">PMID:17714442</ref> <ref name="H">PMID:15385475</ref>  While the exact mechanism for immune evasion remains unknown, several theories have been put forth.  One popular theory maintains that VlsE masks other surface antigens by coating the surface of the bacteria, thereby sterically blocking the antigens from antibody binding.  This is similar to other pathogens with variable regions, such as [http://en.wikipedia.org/wiki/Trypanosoma_brucei Trypanosoma brucei], the protozoa responsible for African sleeping sickness and [http://en.wikipedia.org/wiki/Neisseria_gonorrhoeae Neisseria gonorrhea], the bacterial cause of gonorrhea.  However, recent studies have cast doubt on this theory.  An alternate theory provides that VlsE directly stimulates B cell antibody production independent of T-cells.  The robust response elicited is thought to override antibody production against other antigens.<ref name="G" /> 
<br>
 
 
 
 
 
 
<table width='400' align='left' cellpadding='5'><tr><td rowspan='2'>&nbsp;</td><td bgcolor='#eeeeee'><applet load='1l8w.pdb' size='400' frame='true' align='right' scene='Studio:G5SecL01/Chart_main/4' /></td></tr><tr><td bgcolor='#eeeeee'><center>'''VlsE''' ([[1l8w]]), resolution 2.3&Aring; (<scene name='Studio:G5SecL01/Chart_main/4'>Original</scene>). <br>
Highlight: <scene name='Studio:G5SecL01/Chart_main/3'>IR6</scene>,  <scene name='Studio:G5SecL01/Chart_vr_seagreen/1'>VR</scene>,    <scene name='Studio:G5SecL01/Chart_ir1_yellow/1'>IR1</scene>,  <scene name='Studio:G5SecL01/Chart_ir2_yellow/1'>IR2</scene>,  <scene name='Studio:G5SecL01/Chart_ir3_yellow/1'>IR3</scene>,    <scene name='Studio:G5SecL01/Chart_ir4_yellow/1'>IR4</scene>,    <scene name='Studio:G5SecL01/Chart_ir5_yellow/1'>IR5</scene>. <br>
<br></center></td></tr></table>
 
==C<sub>6</sub> Diagnostic Testing==
 
 
Throughout the course of the disease, IR<sub>6</sub> produces a strong antibody response that can be identified from early to late phases.  Applications in diagnostic testing have been identified as a result of this strong immune response and IR<sub>6</sub>’s relative invariability across strains.<ref name="I">PMID:10565920</ref> <ref name="F" />  A C<sub>6</sub> [http://en.wikipedia.org/wiki/ELISA ELISA] test has been developed which uses a 26 amino acid synthetic peptide, C<sub>6</sub>, containing the IR<sub>6</sub> sequence.  Results show 99% specificity and 100% precision with high sensitivity.  In fact, OspA vaccination does not influence C6 specificity; therefore, C<sub>6</sub> ELISA tests are valuable diagnostic tools.<ref name="I" />  The CDC currently recommends a [http://www.cdc.gov/lyme/healthcare/clinician_twotier.html two-step test] incorporating first a polyvalent, whole-cell [http://en.wikipedia.org/wiki/Sonicate sonicate] (WCS) [http://en.wikipedia.org/wiki/Immunofluorescence_assay immunofluorescent assay].  If results are positive, this is followed by IgG and IgM WCS [http://en.wikipedia.org/wiki/Western_blot Western blots] to eliminate false positives.<ref name="J">PMID:21865190</ref>  Therefore, this one-step ELISA test presents an accurate and economical alternative to the current two-step model.<ref name="I" /> <br>
 
==Additional Links==
[http://en.wikipedia.org/wiki/Lyme_disease_microbiology Lyme Disease Microbiology]<br>
[http://www.cdc.gov/lyme/ CDC Lyme Disease Page]<br>
[http://en.wikipedia.org/wiki/Lyme_disease Lyme Disease]<br>
[http://www.cdc.gov/about/grand-rounds/archives/2011/pdfs/PHGRLymeMay2011.pdf Ecology, Epidemiology, and Prevention of Lyme Disease- CDC]<br>
[http://en.wikipedia.org/wiki/Antigenic_variation Antigenic Variation]<br>
 
 
 
 
 
 
 
 
 
==References==
{{reflist}}
 
 
<small>''Optimal Resolution 1280x1024''</small>
Retrieved from "https://proteopedia.org/User:Marvin_O%27Neal/VlsE"